Showing 3501-3510 of 7760 results for "".
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- June 2022 Marks Scleroderma Awareness Monthhttps://practicaldermatology.com/news/june-2022-marks-scleroderma-awareness-month/2461222/June is Scleroderma Awareness Month, and "Know Scleroderma" is the National Scleroderma Foundation's theme for 2022. Throughout the month, the Foundation will post videos and photos of individuals affected by scleroderma on its
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers-1/2461215/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston, Texas. He
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic derma
- Study: All Moisturizer Types Equally Effectivehttps://practicaldermatology.com/news/study-all-moisturizer-types-equally-effective/2461209/No one type of moisturizer is better than another, according to the Best Emollients for Eczema trial. This study, the first to directly compare different types of moisturizers, highlights the importance of patient education and choice when deciding which moisturizers to use for children
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.